Drug Profile
Research programme: biodefense therapeutics - VenatoRx Pharmaceuticals
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator VenatoRx Pharmaceuticals
- Class
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Hepatitis B; Mycoses; Parasitic infections
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Hepatitis-B in USA
- 25 Mar 2019 Biodefense therapeutics is still in early research for Hepatitis B in USA
- 28 Mar 2018 No recent reports of development identified for research development in Bacterial-infections in USA